The developed diagnostic algorithm, which includes PTN, FGF-21, AST, and sex, demonstrates strong performance independent of gender, making it a valuable tool for identifying MASH in morbidly obese subjects. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatohepatitis.